(MDCO/EGRX)—Musings on the Angiomax en banc rehearing: https://www.statnews.com/pharmalot/2016/05/05/appeals-court-patent-drug-makers/ Reminder: A win for MDCO is bullish for EGRX , even though EGRX is a not a party to this lawsuit.